CIA: CLL VR (Coronavirus Immunology Analysis study: CLL vaccination response)

Project summary:

This study aims to understand, at a qualitative and quantitative level, immune response durability in 'real-life settings' of different vaccination regimens in individuals with a diagnosis of chronic lymphocytic leukaemia (CLL). To achieve this, we will track longitudinal immunity, analysing serum antibody titre and  live virus neutralisation, both to wild-type and variant targets. In terms of T cell immunity, we will track durability of response and  frequency to wild-type and variant epitopes using a range of approaches.

Funders

National Core Studies Programme (NCS) immunity

Leader researcher:

Professor Paul Moss

Lead institution:

University of Birmingham

Vaccine type:

AstraZeneca
Pfizer